Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells (Q46956224)

26 December 2017

title

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells (English)

1 reference

26 December 2017

1 reference

11

1 reference

26 December 2017

author name string

Papa V

1

1 reference

26 December 2017

Tazzari PL

2

1 reference

26 December 2017

Chiarini F

3

1 reference

26 December 2017

Cappellini A

4

1 reference

26 December 2017

Ricci F

5

1 reference

26 December 2017

Billi AM

6

1 reference

26 December 2017

Evangelisti C

7

1 reference

26 December 2017

Ottaviani E

8

1 reference

26 December 2017

Martinelli G

9

1 reference

26 December 2017

Testoni N

10

1 reference

26 December 2017

Martelli AM

12

1 reference

26 December 2017

publication date

11 October 2007

1 reference

26 December 2017

published in

Leukemia

1 reference

26 December 2017

volume

22

1 reference

26 December 2017

page(s)

147-160

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404980

exact match

0 references

cites work

Structure, regulation and function of PKB/AKT--a major therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

mTOR, a new therapeutic target in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

BID as a double agent in cell life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

NF-kappa B signaling and carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Tumor progression--targets for differential therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Perturbations of the AKT signaling pathway in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

The Akt/PKB pathway: molecular target for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Targeting the PI3K-Akt pathway in human cancer: rationale and promise

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Constitutive NF-κB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-differentiated HL-60 cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Apoptosis effector mechanisms: a requiem performed in different keys

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

p21-activated kinase (PAK1) is phosphorylated and activated by 3-phosphoinositide-dependent kinase-1 (PDK1).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Simultaneous induction of apoptotic and survival signaling pathways in macrophage-like THP-1 cells by Shiga toxin 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Pgp and FLT3: identification and modulation of two proteins that lead to chemotherapy resistance in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

A Phase 2 study of perifosine in advanced or metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27(Kip1) and control of cyclin D1 expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Involvement of caspase-2 long isoform in Fas-mediated cell death of human leukemic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Caspase-2 can function upstream of bid cleavage in the TRAIL apoptosis pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

ROS-triggered caspase 2 activation and feedback amplification loop in beta-carotene-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404980

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404980

1 reference

26 December 2017

PubMed ID

17928881

1 reference

26 December 2017